ISU Abxis Co., Ltd. (KOSDAQ:086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,495.00
+325.00 (10.25%)
At close: Jun 29, 2026
Market Cap142.51B -23.9%
Revenue (ttm)58.94B +15.7%
Net Income-2.12B
EPS-53.91
Shares Out 40.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume126,273
Open3,055.00
Previous Close3,170.00
Day's Range3,055.00 - 3,495.00
52-Week Range3,000.00 - 6,350.00
Beta0.47
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 178
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

Financial Statements